Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
10/2007
10/11/2007US20070238777 Use of Furan Alkyls for Preparing a Drug for Treating Obesity and Cosmetically Treating Overweight
10/11/2007US20070238776 Novel Pyrroles Having Hypolipidemic Hypocholesteremic Activities, Process for Their Preparation and Pharmaceutical Compositions Containing Them and Their Use in Medicine
10/11/2007US20070238775 Modulators of ATP-binding cassette transporters
10/11/2007US20070238774 Carvedilol dihydrogen phosphate dihydrate; crystal structure; x-ray patterns; mixed venous/arterial vasodilation; non-cardioselective, beta-adrenergic blocking agents; hypotensive agents, congestive heart failure; angina;water solubility; stability; prolonged G.I. bioavailabilty in pH regions
10/11/2007US20070238773 Compositions and methods of treatment using modulators of motoneuron diseases
10/11/2007US20070238772 Use of Metronidazole for Preparing a Pharmaceutical Composition for Treating a Cutaneous Vascularisation Disorder
10/11/2007US20070238771 Indoles and benzoimidazoles as histamine H4 receptor modulators
10/11/2007US20070238770 Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
10/11/2007US20070238769 Bone Densifying Agent Characterized By Use Of Cathepsin K Inhibitor With Pth
10/11/2007US20070238768 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
10/11/2007US20070238767 e.g. 4,5-Dihydro-2-(2,4-dihydroxyphenyl)-thiazole-4(S)-carboxylic acid; ferrochelatase; thalassemia, anemia; diagnosing and treating pathological conditions associated with excess of trivalent metals (such as Fe, Al and Cr)
10/11/2007US20070238766 Imidazo[2,1-b]-1,3,4-thiadiazole sulfonamides
10/11/2007US20070238765 Heterocyclic GABAA subtype selective receptor modulators
10/11/2007US20070238764 Use of Sphingoid Base Associated with Nicotinic Acid or a Nicotinic Acid Amide in the Form of Depigmentation Agent
10/11/2007US20070238763 Urea derivatives as integrin a4 antagonists
10/11/2007US20070238762 Use of Antagonists of Hepatic Sympathetic Nerve Activity
10/11/2007US20070238761 Use of pyridoxamine to treat and/or prevent disease processes
10/11/2007US20070238760 Diagnosis and treatment of human kidney diseases
10/11/2007US20070238759 Novel Polymorph V of Torasemide
10/11/2007US20070238758 Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
10/11/2007US20070238757 Novel treatment
10/11/2007US20070238756 Combinations of dipeptidyl peptidase iv inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
10/11/2007US20070238755 Methods to treat and/or prevent radiation- and/or chemical-induced toxicity in non-malignant tissue
10/11/2007US20070238754 1-Cyclohexylmethyl-5-(2,5-dimethoxy-phenyl)-2-methyl-1H-pyrrole-3-carboxylic acid cyclohexylamide and 2-(5-Chloro-2-methoxy-phenyl)-1-(2-cyclohexyl-ethyl)-5-methyl-1H-imidazole-4-carboxylic acid cyclohexylamide; treating obesity, eating disorders; antidiabetic agents; antiinflammatory agents; drug abuse
10/11/2007US20070238753 Pharmaceutical Compositions as Inhibitors of Dipeptidyl Peptidase-IV (DPP-IV)
10/11/2007US20070238752 Muscarinic Acetylcholine Receptor Antagonists
10/11/2007US20070238751 Muscarinic Acetylcholine Receptor Antagonists
10/11/2007US20070238750 Pure isomers of tritoqualine
10/11/2007US20070238749 Alpha2delta ligands for the treatment of fibromyalgia and other disorders
10/11/2007US20070238748 Methods for Treating Diseases with 4-Hydroxybenzomorphans
10/11/2007US20070238747 Rifamycin analogs and uses thereof
10/11/2007US20070238746 Thiazolyl-dihydro-chinazoline
10/11/2007US20070238745 PI3K-Akt Pathway Inhibitors
10/11/2007US20070238744 Use of 6-(2-Tolyl)-Triazolopyrimidines as Fungicides, Novel 6-(2-Tolyl)-Triazolopyrimidines, Method for the Production Thereof, Used There of for Controlling Harmful Fungi, and Agents Containing the Same
10/11/2007US20070238743 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
10/11/2007US20070238742 Methods of preparation and resolution of e/z isomers of vinylfuro[2,3-d]pyrimidine and their biological activities and related compositions and methods of treatment
10/11/2007US20070238741 Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine
10/11/2007US20070238740 Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
10/11/2007US20070238739 Process for purifying N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-n-ethylacetamide (zaleplon) and crystalline forms of zaleplon accessible with the process
10/11/2007US20070238738 Crystalline ziprasidone HCI and processes for preparation thereof
10/11/2007US20070238737 N-[6-[cis-3,5-dimethyl-1-piperazinyl]-3-(methyloxy)-2-pyridinyl]-3-fluoro-4-(5-methyl-2-furanyl)benzenesulfonamide; for treating gastrointestinal disorders; agonistic activity at the growth hormone secretagogue (GHS) receptors
10/11/2007US20070238736 4-(1-Piperazinyl)-2(1H)-quinolone and 4-(1-piperazinyl)quinoline derivatives, e.g., 4-[4-(Benzo [1,3]dioxole-5-carbonyl)-piperazin-1-yl]-1-(4-fluoro-benzyl)-2-oxo-1,2-dihydro-quinoline-3-carbonitrile; antitumor and angiogenesis inhibitor, antiinflammatory, antidiabetic agent, autoimmune disorder
10/11/2007US20070238735 Cyclooxygenase-2 selective inhibitors, compositions and methods of use
10/11/2007US20070238734 Jnk inhibitors
10/11/2007US20070238733 Drugs for various disorders such as sodium channel modulators, cardiovascular disorders, antiarrhythmia agents ar nervous system disorders
10/11/2007US20070238732 Brimonidine and timolol compositions
10/11/2007US20070238731 Dna-Pk Inhibitors
10/11/2007US20070238730 Phosphatidylinositol-3-kinases inhibitors; antitumor, antiinflammatory agents; autoimmune diseases, allagies, respiratory disorders
10/11/2007US20070238729 Dna-pk inhibitors
10/11/2007US20070238728 Novel dipeptidyl peptidase iv inhibitors, process for their preparation and compositions containing them
10/11/2007US20070238727 5-Substituted 1-Phenyl-1,5-Dihydro-Pyrido[3,2-B]Indol-2-Ones and Analogs as Anti-Virals
10/11/2007US20070238726 Heterobicyclic pyrazole compounds and methods of use
10/11/2007US20070238725 Therapeutic combinations for the treatment or prevention of psychotic disorders
10/11/2007US20070238724 3-(1-methylpiperidin-4-yl)-5-(1-naphthylsulfonyl)-1H-indazole, central nervous system disorder
10/11/2007US20070238723 Benzoxazinyl-amidocyclopentyl-heterocyclic modulators of chemokine receptors
10/11/2007US20070238722 N-sulfonyl-4-methyleneamino-3-hydroxy-2-pyridones
10/11/2007US20070238721 Highly Selective Novel Amidation Method
10/11/2007US20070238720 Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
10/11/2007US20070238719 Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
10/11/2007US20070238718 Thiazolyl-dihydro-indazole
10/11/2007US20070238717 Neuroprotection with Beta-Lactam Compounds
10/11/2007US20070238716 Statin stabilizing dosage formulations
10/11/2007US20070238715 e.g. 1-(4-amino-3-chloro-5-trifluoromethyl-benzyl)-2-oxo-2-[4-(2-piperidin-1-yl-ethyl)-piperidin-1-yl]-ethyl 4-(2-oxo-1 ,2,4,5-tetrahydro-benzo[d][1,3]diazepin-3-yl)-piperidine-1-carboxylate; calcitonin gene related peptide antagonist; migraine or cluster headaches, non-insulin-dependent diabetes
10/11/2007US20070238714 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
10/11/2007US20070238713 Methods for prevention and treatment of conditions arising from local estrogen deficiency
10/11/2007US20070238712 19-Nor-Vitamin D Analogs with 1,2 or 3,2 Heterocyclic Ring
10/11/2007US20070238711 Combination Therapy with Glatiramer Acetate and Minocycline for the Treatment of Multiple Sclerosis
10/11/2007US20070238710 mitogen-activated protein kinase inhibitors such as 3,4-Dihydroxy-propane-1-amino-sulfonic acid [3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-amide, useful in the treatment of cancer and other hyperproliferative diseases
10/11/2007US20070238709 lipophilic cationic moiety linked by to an antioxidant; a salt forming anion; does not exhibit reactivity against the lipophilic cationic moiety; Parkinson's, Alzheimer's disease, Huntington's Chorea and Friedreich's Ataxia
10/11/2007US20070238708 Acute Inflammatory Condition Treatment
10/11/2007US20070238707 Comprising a dosage form of zoledronic acid and a medium chain ftty acid orsalt for delivey to the intestines; controlled release; delayed release;time-release agents; increased bioavailability, adsorption; tablets; capsules
10/11/2007US20070238706 2-Methylene-1Alpha,25-Dihydroxy-19,21-Dinorvitamin D3 Analogs and Uses Thereof
10/11/2007US20070238705 2-Methylene-1Alpha,25-Dihydroxy-18,19,21-Trinorvitamin D3 and Uses Thereof
10/11/2007US20070238704 2-Substituted-1Alpha,25-Dihydroxy-19,26,27-Trinor Vitamin D Analogs and Uses Thereof
10/11/2007US20070238703 1 alpha -hydroxy-2-[3'-hydroxypropylidene]-20-methyl-19, 24, 25, 26, 27-pentanorvitamin D3, used as an anticarcinogenic agent, for the treatment of skin disorders, autoimmune diseases, inflammatory diseases, renal osteodystrophy, and/or prevention of obesity
10/11/2007US20070238702 Metabolic bone disease; psoriasis; leukemia; colon, breast, prostate, skin, lung cancer; multiple sclerosis; lupus; diabetes mellitus; host versus graft reaction; rejection of organ transplants; an inflammatory disease selected from rheumatoid arthritis, asthma, psoriasis
10/11/2007US20070238701 2-Methylene-1alpha-Hydroxy-18,19,21-Trinorvitamin D3 Analogs and Uses Thereof
10/11/2007US20070238699 Compounds for the treatment of proliferative disorders
10/11/2007US20070238698 Method for manufacturing drinking water having chitosan
10/11/2007US20070238697 Pharmaceutical compositions and methods relating to fucans
10/11/2007US20070238696 Dosage unit for cardioprotection
10/11/2007US20070238695 Synergistic method for the treatment of joint dysfunction using S-Adenosyl-Methionine and a patented mixture of cetylated fatty acids
10/11/2007US20070238694 Purine compounds and methods of use thereof
10/11/2007US20070238693 Genetic modification of the lung as a portal for gene delivery
10/11/2007US20070238690 Modulation of glucagon receptor expression
10/11/2007US20070238689 Modulation of glucagon receptor expression
10/11/2007US20070238688 Modulation of glucagon receptor expression
10/11/2007US20070238687 Modulation of glucagon receptor expression
10/11/2007US20070238686 Inhibition of Chronic Myelogenous Leukemic Cell Growth By Liposomal-Antisense Oligodeoxy-Nucleotides Targeting To Grb2 or Crk1
10/11/2007US20070238685 using gutless adenovirus vector; gene therapy; gutless means incapable of expressing any adenovirus antigens
10/11/2007US20070238684 For an improved in vitro and in vivo transformation of particular cells, for example for somatic gene therapy; diagnosis, increased infectivity for cells of low susceptibility, such as haematopoietic cells
10/11/2007US20070238683 Modified and stabilized gdf propeptides and uses thereof
10/11/2007US20070238682 Heat shock rna and its use in activation of heat shock transcription factor and treatment of cancer, inflammation, ischemia, neurodegeneration, age-related diseases, hiv infection, deafness, and related disorders
10/11/2007US20070238681 Modulation of ace2 expression
10/11/2007US20070238677 Pharmaceutical Composition Containing Hshrd3
10/11/2007US20070238676 Polynucleotides for Reducing Respiratory Syncytial Virus Gene Expression
10/11/2007US20070238674 Tra combination therapies
10/11/2007US20070238673 Ceramide derivatives as modulators of immunity and autoimmunity
10/11/2007US20070238672 Co-administration of adenosine a1 receptor antagonists and anticonvulsants
10/11/2007US20070238653 Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof
1 ... 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 3563 3564 3565 3566 3567 3568 ... 7860